Pharmaceutical company Enlivex Therapeutics (ENLV) completed the initial dosing and follow-up of patients with psoriatic arthritis treated with Allocetra in November. This Phase I trial evaluates the safety, tolerability, and potential effectiveness of Allocetra as a treatment for psoriatic arthritis. The company notes there have been no adverse events following the first joint injections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex Therapeutics notes the study will last for 12 months with primary endpoints focused on adverse events. Another endpoint will evaluate the reduction of pain following treatment with Allocetra. Company CEO Dr. Oren Hershkovitz said the trial “potentially presents a substantial market opportunity for Enlivex.”
ENLV stock is up 2.86% as of this writing and has increased 2.91% over the last three months.
